COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,722 Articles (22,913 medRxiv, 8,809 bioRxiv)

Most recent first Previous |  Page 490: Articles 4891-4900  | Next

Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >=50 years in Ontario, Canada
Grewal, R., Buchan, S. A., Nguyen, L., Nasreen, S., Austin, P. C., Brown, K. A., Gubbay, J., Lee, N., Schwartz, K. L., Tadrous, M., Wilson, K., Wilson, S. E., Kwong, J. C., on behalf of the CIRN Provincial Collaborative Network investigators
10.1101/2023.04.11.23288403 — Posted: 2023-04-11
A methodological framework for assessing the benefit of SARS-CoV-2 vaccination following previous infection: case study of five to eleven year olds in the UK
Pagel, C., Wilde, H., Tomlinson, C., Mateen, B. A., Brown, K.
10.1101/2023.04.11.23288409 — Posted: 2023-04-11
Infants and young children generate more durable antibody responses to SARS-CoV-2 infection than adults
Joshi, D., Nyhoff, L. E., Zarnitsyna, V. I., Moreno, A., Manning, K., Linderman, S., Burrell, A., Stephens, K., Norwood, C., Mantus, G. E., Ahmed, R., Anderson, E. J., Staat, M. A., Suthar, M. S., Wrammert, J.
10.1101/2023.04.10.23288360 — Posted: 2023-04-11
Comprehensive analysis of nasal IgA antibodies induced by intranasal administration of the SARS-CoV-2 spike protein
Waki, K., Tani, H., Saga, Y., Shimada, T., Yamazaki, E., Koike, S., Okada, N., Isobe, M., Kurosawa, N.
10.1101/2023.04.10.536311 — Posted: 2023-04-11
Global surveillance of novel SARS-CoV-2 variants
Patel, S., Cumming, F., Mayers, C., Charlett, A., Riley, S.
10.1101/2023.04.10.23288358 — Posted: 2023-04-10
A cross-sectional study of the association between COVID-19 infection and psychological distress in Japanese workers
Tesen, H., Konno, Y., Tateishi, S., Tsuji, M., Ogami, A., Nagata, T., Matsugaki, R., Yoshimura, R., Fujino, Y., Mafune, K.
10.1101/2023.04.08.23288312 — Posted: 2023-04-10
Unbiased spectral cytometry immunome characterization predicts COVID-19 mRNA vaccine failure in older adults and patients with lymphoid malignancies.
HERNANDEZ-VAZQUEZ, J., CAL-SABATER, P., ARRIBAS-RODRIGUEZ, E., FIZ-LOPEZ, A., PEREZ-SEGURADO, C., MARTIN-MUNOZ, A., DE PRADO-SANTOS, A., DE LA FUENTE-GRACIANI, I., PEREZ-GONZALEZ, S., GUTIERREZ, S., TELLERIA, P., NOVOA, C., ROJO-RELLO, S., GARCIA-BLESA, A., SEDANO, R., MARTINEZ-GARCIA, A. M., GARCINUNO-PEREZ, S., DOMINGUEZ-GIL, M., HERNAN-GARCIA, C., GUERRA, M. M., MUNOZ-SANCHEZ, E., BARRAGAN-PEREZ, C., DIEZ-MORALES, S., CASAZZA-DONNARUMMA, O., RAMOS-POLLO, D., SANTAMARTA-SOLLA, N., ALVAREZ-MANZANARES, P. M., BRAVO, S., GARCIA-ALONSO, C., TESEDO-NIETO, A., LOPEZ-MORENO, E. C., CABRERA-SANZ, M.
10.1101/2023.04.10.23288350 — Posted: 2023-04-10
NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing
Feng, W., Beer, J., Hao, Q., Ariyapala, I. S., Sahajan, A., Komarov, A., Cha, K., Moua, M., Qiu, X., Xu, X., Iyengar, S., Yoshimura, T., Nagaraj, R., Wang, L., Yu, M., Engel, K., Zhen, L., Xue, W., Lee, C.-j., Park, C. H., Peng, C., Zhang, K., Grzybowski, A., Hahm, J., Schmidt, S. V., Odainic, A., Spitzer, J., Bonn COVIMMUNE Consortium, , Buddika, K., Kuo, D., Fang, L., Zhang, B., Chen, S., Latz, E., Yin, Y., Luo, Y., Ma, X.-J.
10.1101/2023.04.09.536130 — Posted: 2023-04-10
Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
Liu, L., Casner, R. G., Guo, Y., Wang, Q., Iketani, S., Chan, J. F.-W., Yu, J., Dadonaite, B., Nair, M. S., Mohri, H., Reddem, E. R., Yuan, S., Poon, V. K.-M., Chan, C. C.-S., Yuen, K.-Y., Sheng, Z., Huang, Y., Bloom, J. D., Shapiro, L., Ho, D. D.
10.1101/2023.04.08.536123 — Posted: 2023-04-10
SARS-CoV-2's evolutionary capacity is mostly driven by host antiviral molecules
Lamb, K. D., Luka, M. M., Saathoff, M., Orton, R., Phan, M., Cotten, M., Yuan, K., Robertson, D. L.
10.1101/2023.04.07.536037 — Posted: 2023-04-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).